Thymosin Alpha-1 vs Thymalin: Which Is Better for Immunity?
Should I use thymosin alpha-1 or thymalin?
Thymosin alpha-1 scores 7.3 and thymalin 5.9, and the gap is about evidence rather than mechanism. Thymosin alpha-1 is a defined molecule with modern meta-analyses behind it and a prescription route. Thymalin's entire human case traces to one Russian research group, and it reaches you through the gray market as an undefined extract.
- Thymosin alpha-1 7.3, thymalin 5.9. On immune function, the use case both are actually sold for, the subratings are 9.0 against 4.2.
- Thymosin alpha-1 is one defined 28-amino-acid peptide. Thymalin is a mixture of peptides extracted from calf thymus, so you cannot know what is in the vial.
- Both converge on the same endpoint, T-cell maturation and CD4/CD8 normalization, so running both together is redundant rather than additive.
- Access decides a lot here. Thymosin alpha-1 is a compounded prescription. Thymalin is gray market with no batch testing available, because an undefined extract is rarely testable at all.
- Thymalin's headline is a 2 to 4 fold elderly mortality drop (Khavinson 2003). It has never been independently replicated outside that one program, which is why this comparison carries low confidence.
- Neither one is a general wellness product. Both are contraindicated in autoimmune disease, transplant status, immunosuppressive therapy, pregnancy and lactation.
At a Glance
Thymosin Alpha-1
- Efficacy 3.8
- Breadth 4.4
- Evidence 4.1
- Speed 3.0
- Durability 3.2
- Bioindividuality 3.6
- Safety Risk 1.6
- Side Effects 1.8
- Cost 2.9
- Effort 2.6
- Opportunity Cost 2.0
- Dependency 1.6
- Reversibility 1.6
- Immune Function
- Geriatric
- Anti Inflammatory
- Liver Detox
Defined 28-amino-acid thymic peptide, sold internationally as thymalfasin. BioHarmony 7.3, strong recommend.
Thymalin
- Efficacy 3.8
- Breadth 3.4
- Evidence 3.6
- Speed 3.2
- Durability 2.7
- Bioindividuality 3.2
- Safety Risk 2.4
- Side Effects 2.3
- Cost 2.8
- Effort 3.2
- Opportunity Cost 3.0
- Dependency 2.3
- Reversibility 1.8
- Immune Function
- Longevity
- Geriatric
- Anti Inflammatory
Undefined calf-thymus peptide extract from the Khavinson bioregulator program. BioHarmony 5.9, worth trying.
Head-to-Head Verdict
| Use Case | Winner | Rationale |
|---|---|---|
| Immune Function | Thymosin Alpha-1 | Thymosin alpha-1 9.0 against thymalin 4.2, and this is the row that decides the page. Cao 2024 pooled 39 acute COPD exacerbation trials covering 3,329 patients and found improved lung function, blood gases, hospital stay and T-cell markers. Thymalin's immune case rests on a stem-cell culture study (Khavinson 2020) and a 1997 characterization paper. |
| Respiratory | Thymosin Alpha-1 | Thymosin alpha-1 6.5 against thymalin 2.1. Both claim respiratory benefit, and only one has the trial base for it. Cao 2024 is a 39-trial meta-analysis in acute COPD exacerbation. Thymalin's respiratory claims in ARDS, chronic bronchitis and severe COVID come through Linkova 2023, where every study is small and from the same program. |
| Geriatric | Thymosin Alpha-1 | Thymosin alpha-1 7.5 against thymalin 2.6. Both target the immunosenescent older adult, which is the population with the clearest reason to respond. Thymosin alpha-1 has a double-blind placebo-controlled influenza vaccine-adjuvant trial in older men (Gravenstein 1989). Thymalin's geriatric case is the same single-source, non-blinded elderly cohort that carries all of its other claims. |
| Anti Inflammatory | Thymosin Alpha-1 | Thymosin alpha-1 7.0 against thymalin 2.5. Thymalin's inflammatory evidence is one adjunct COVID study reporting faster decline in IL-6, CRP and D-dimer (Khavinson 2021), suggestive and unreplicated. Thymosin alpha-1 carries a 1,106-patient phase 3 sepsis trial (Wu 2025) and a 5-trial pancreatitis meta-analysis (Tian 2025) that tracked immune markers and infection rates directly. |
| Healthspan | Thymosin Alpha-1 | Thymosin alpha-1 6.5 against thymalin 2.4. Neither has a healthspan endpoint of its own, so this row is decided by which immune case you can trust to carry over. Thymosin alpha-1's rests on modern meta-analyses. Thymalin's rests on a cohort that claimed fewer cardiovascular, endocrine and respiratory problems without isolating any of them. |
| Longevity | Tie | Call this even, and notice that the subratings do not. Thymosin alpha-1 scores 6.0 and thymalin 4.0, but thymosin alpha-1 has no longevity endpoint at all: its number is inherited from immune credibility. Thymalin's 4.0 rests on the single-source Khavinson 2003 cohort reporting mortality roughly 2 to 4 fold lower over 6 years. An unreplicated result and an absent one are both unusable. |
| Cardiovascular | Tie | Even, and neither number means much. Thymosin alpha-1 scores 4.0 on cardiovascular relevance that is secondary to sepsis outcomes in Wu 2013, with no primary cardiovascular indication. Thymalin scores 1.9 on Cherkashin 2002, a tiny non-blinded single-program hemodynamics study. Pick either of these for your heart and you are acting on nothing. |
| Recovery Repair | Tie | Even. Thymosin alpha-1's 4.0 comes from immune-mediated infection control and post-illness recovery, with no athletic or connective-tissue trial behind it. Thymalin's 2.2 comes from Boiko 2024, a rat mandible regeneration model. Neither belongs in a training recovery stack, and the 2-point subrating gap does not describe a real difference in what you would get. |
Cost Comparison
| Intervention | Monthly Cost | Notes |
|---|---|---|
| Thymosin Alpha-1 | $100 to $400 | Priced 2026-09-07 through a US compounding pharmacy on a prescription, at the standard twice-weekly subcutaneous protocol the source report uses. Branded international product (thymalfasin, sold as Zadaxin) costs materially more. The exact dosing schedule and the per-vial arithmetic live on the thymosin alpha-1 report, not here. |
| Thymalin | $113 to $590 | ESTIMATE, priced 2026-09-07 through the research-chemical channel. Gray-market 10 mg vials run about $45 to $59, and a 5 to 10 day course at 5 to 10 mg a day works out to 25 to 100 mg, so the month a course runs costs between roughly 2.5 vials and 10 vials. This is a channel estimate, not a measured price. |
| The difference | Overlapping ranges, and no cost argument for thymalin | The ranges overlap, so cost does not separate these two. The cheaper floor belongs to thymosin alpha-1 at $100, and the higher ceiling belongs to thymalin at $590 for the month a course runs.Being gray market usually buys you a discount. Here it does not. You are paying a comparable price for an undefined extract instead of a defined molecule, which is the clearest reason the score gap is not just an evidence-snobbery artifact. |
When to Switch
Both are course-based rather than continuous, and both give you a first impression fast, so early feel tells you almost nothing about whether either is working. Thymosin alpha-1's first noticeable change lands around day 7 with full effect near day 14, and its assessment window is 4 weeks. Thymalin moves slightly faster on paper, first noticeable around day 5 and full effect near day 10, with a 2-week window. Both of those onset figures are estimates, not measured, so judge at the end of the window rather than in the first few days.
Move from thymalin to thymosin alpha-1 as the default whenever a prescriber is available: you get a defined molecule, a testable product and modern meta-analyses for a comparable monthly cost. Move the other way only for a reason you can state out loud, which in practice means you are deliberately running the Khavinson bioregulator program and accept that the human evidence is single-source.
Do not overlap them. Both push T-cell maturation through thymic-hormone signaling, so running both stacks cost, injection burden and sourcing risk on top of each other with no separate pathway to show for it. Stop one, finish the course on the other, and reassess at that side's own window.
Who Should Pick What?
Adult over 40 with signs of immune aging or poor vaccine response
Thymosin Alpha-1
Geriatric subrating 7.5 against 2.6, and there is a double-blind placebo-controlled influenza vaccine-adjuvant trial in older men behind it (Gravenstein 1989). Thymalin targets the same population with a non-blinded single-source cohort.
Frequent traveler wanting break-glass cover for high-exposure windows
Thymosin Alpha-1
Immune function 9.0 against 4.2, and this is the one use in the comparison where I have direct experience. I have used thymosin alpha-1 this way and stopped short of daily use. I have never used thymalin.
Recovering from illness, surgery or immune suppression, with a clinician involved
Thymosin Alpha-1
This is the setting the modern trial base actually covers: acute COPD exacerbation (Cao 2024), severe acute pancreatitis (Tian 2025), sepsis (Wu 2025). It is also the setting where a prescription route and a characterized product matter most.
Deliberately running the Khavinson peptide bioregulator program
Thymalin
Thymalin is the immune pillar of that program, and nothing else substitutes for it if that is the framework you are testing. Go in knowing the whole human case is single-source, and treat it as an experiment you judge on your own response.
Chasing the elderly mortality result specifically
Tie
Neither. The 2 to 4 fold mortality drop in Khavinson 2003 is the most eye-catching number in this comparison and the weakest supported: one 266-person cohort, one research group, no independent replication in over twenty years. Thymosin alpha-1 has no longevity endpoint to offer instead.
Autoimmune disease, transplant recipient, or on immunosuppressive therapy
Tie
Neither. Autoimmune disease, transplant status and ongoing immunosuppressive therapy are listed contraindications on both reports. Deliberately pushing T-cell immunity is the wrong direction for all three.
Pregnant, lactating, or cannot verify sterile sourcing
Tie
Neither. Pregnancy and lactation are contraindicated on both. Thymalin adds bovine-protein allergy and a batch-testing problem you usually cannot solve. Thymosin alpha-1 adds an FDA compounding-concern listing that makes pharmacy provenance non-optional.
Research Highlights
-
Mechanism Difference
Thymosin alpha-1 and thymalin are mechanistically redundant. Thymosin alpha-1 is a defined 28-amino-acid peptide that signals through TLR9 and TLR2 on dendritic cells, activates NF-kB, drives Th1 polarization, normalizes the CD4/CD8 ratio and supports natural killer cells.Thymalin is a low-molecular-weight peptide mixture extracted from calf thymus, reported to stimulate T-cell immunity and push hematopoietic stem cells toward mature T-lymphocytes. Both arrive at the same endpoint, T-cell maturation and CD4/CD8 normalization, so combining them adds cost and injection burden without adding a pathway.
-
Safety Comparison
Neither peptide's main risk is its own pharmacology. Thymosin alpha-1 looked placebo-like in the largest controlled dataset: the 1,106-patient TESTS sepsis trial (Wu 2025) reported adverse events of 66.4% against 67.6% on placebo with no unexpected serious drug-related events.Thymalin is reported as well tolerated across four decades of Russian use, but that record comes without Western pharmacovigilance, so absence of reported harm partly reflects absence of monitoring. Both are contraindicated in autoimmune disease, transplant status, immunosuppressive therapy, pregnancy and lactation. Thymalin adds bovine-protein allergy.
-
Cost Comparison
Thymosin alpha-1 runs about $100 to $400 a month through a US compounding pharmacy, and thymalin about $113 to $590 for the month a course runs through the research-chemical channel, both priced 2026-09-07. The thymalin figure is an estimate built from $45 to $59 gray-market vials.The ranges overlap, so cost does not decide this comparison. The gray-market option is not the cheap option here, which removes the usual argument for accepting an undefined extract over a characterized molecule.
-
Editorial Verdict
Thymosin alpha-1 scores 7.3 and thymalin 5.9, and on immune function specifically the subratings are 9.0 against 4.2. Thymosin alpha-1 is the default for anyone who can get a prescription: a defined molecule, modern meta-analyses in acute COPD and pancreatitis, and a phase 3 sepsis trial that came back negative on mortality but clean on safety.Thymalin is defensible only as a deliberate experiment inside the Khavinson bioregulator program. Its human evidence is single-source and unreplicated, which is why this comparison carries low confidence. Neither is a general wellness product.
-
Evidence Quality
The score gap between these two is an evidence gap, not a mechanism gap. Thymosin alpha-1's modern record includes a 39-trial meta-analysis in acute COPD exacerbation (Cao 2024), a 5-trial pancreatitis meta-analysis (Tian 2025), and a 1,106-patient phase 3 sepsis trial (Wu 2025) that found no clear 28-day mortality benefit.Thymalin's human record traces entirely to one St. Petersburg research lineage: a 266-person elderly cohort (Khavinson 2003), a severe-COVID adjunct trial (Kuznik 2022), and a stem-cell culture study (Khavinson 2020). Mostly non-blinded, never independently reproduced.
Frequently Asked Questions
- Is thymosin alpha-1 better than thymalin?
- For almost everyone, yes. Thymosin alpha-1 scores 7.3 against thymalin's 5.9, and on immune function specifically the subratings are 9.0 against 4.2. Thymosin alpha-1 is a defined molecule with modern meta-analyses behind it and a prescription route. The one case for thymalin is a deliberate experiment inside the Khavinson bioregulator program.
- What is the actual difference between the two?
- Thymosin alpha-1 is a single defined 28-amino-acid peptide, sold internationally as thymalfasin. Thymalin is a mixture of peptides extracted from calf thymus, so its exact composition is not defined. That difference drives everything else: what can be trialed, what can be batch-tested, and what a prescriber can legally dispense.
- Can I take thymosin alpha-1 and thymalin together?
- There is no reason to. Both act on the same endpoint, pushing T-cell maturation and normalizing the CD4/CD8 ratio, which makes them redundant rather than complementary. Stacking them doubles the injection burden, the cost and the sourcing risk without adding a separate mechanism. Finish one course, then reassess.
- Is thymalin's mortality result real?
- The study is real and the number is large: a 266-person elderly cohort reporting mortality roughly 2 to 4 fold lower over 6 years (Khavinson 2003). The problem is that every version of it traces to one St. Petersburg research group, with no independent replication in over twenty years. Treat it as an unconfirmed signal, not an established result.
- Which one is cheaper?
- Neither, meaningfully. Thymosin alpha-1 runs about $100 to $400 a month through a compounding pharmacy. Thymalin is estimated at $113 to $590 for the month a course runs, built from $45 to $59 gray-market vials. Both priced 2026-09-07. The ranges overlap, so cost is not a tie-breaker here.
- How long before I know if it is working?
- Judge thymosin alpha-1 at 4 weeks and thymalin at 2 weeks, which are their respective assessment windows. First noticeable change is estimated around day 7 for thymosin alpha-1 and day 5 for thymalin, with full effect near day 14 and day 10. Those onset figures are estimates rather than measured, so the window matters more than the first few days.
- Who should not take either one?
- Anyone with active autoimmune disease or a recent flare, transplant recipients, anyone on immunosuppressive therapy, anyone pregnant or lactating, and anyone in an active cancer protocol without oncologist oversight. Both push immune activity, which is the wrong direction in all of those.Thymalin adds bovine-protein allergy because it is calf-thymus derived. Thymosin alpha-1 adds a drug-testing risk for athletes using non-approved product.
- Has Nick used either of these?
- Thymosin alpha-1, yes, and he stopped using it daily. He travels with it as break-glass immune support for airports, international trips, crowded events and sick contacts, and rates it 7.5 out of 10 personally. He has not noticed dramatic effects beyond not getting sick. He has not tried thymalin.
Evidence Sources
- Systematic review Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: systematic review and meta-analysis (2024) 39 randomized trials, 3,329 patients. Adjunctive thymosin alpha-1 improved lung function, blood gases, hospital stay and T-cell markers, with heterogeneity and risk-of-bias caveats.
- Systematic review Thymosin alpha 1 alleviates inflammation and prevents infection in severe acute pancreatitis: systematic review and meta-analysis (2025) 5 randomized trials, 706 patients. Increased CD4 cells and CD4/CD8 ratio, fewer extrapancreatic infections, lower APACHE II score.
- RCT TESTS phase 3 sepsis trial, BMJ (2025) 1,106 randomized adults with sepsis. No clear 28-day mortality benefit from thymosin alpha-1, with adverse-event rates similar to placebo.
- Systematic review Efficacy of thymosin alpha1 for sepsis: systematic review and meta-analysis of randomized controlled trials (2025) 11 randomized trials, 1,927 patients. Pooled 28-day mortality favored thymosin alpha-1, but the evidence stays heterogeneous and guideline uptake lags.
- RCT ETASS severe sepsis multicenter randomized controlled trial (2013) 361 severe sepsis patients. 28-day mortality 26.0% against 35.0%, relative risk 0.74 with a confidence interval crossing 1.0, and improved mHLA-DR.
- RCT Efficacy of thymosin alpha1 in chronic hepatitis B: randomized controlled trial (1998) 98 patients. Complete virologic response of 40.6% after a 26-week course against 9.4% in controls at 18 months.
- RCT Influenza antibody response in elderly men (1989) Double-blind placebo-controlled trial in older men testing thymosin alpha-1 as an influenza vaccine adjuvant. No toxicity observed.
- Preclinical Thymosin alpha 1 activates dendritic cells through toll-like receptor signaling (2004) Mechanism record supporting dendritic-cell TLR and MyD88 signaling and Th1 antifungal immunity in transplant-mouse models.
- Guideline Certain bulk drug substances for use in compounding that may present significant safety risks, FDA (2026) FDA lists thymosin alpha-1 compounding concerns: immunogenicity, peptide impurities, active-ingredient characterization and inadequate safety information.
- Guideline Practice Guideline Update on Treatment of Chronic Hepatitis B, AASLD and IDSA (2025) Current major-society guidance does not position thymosin alpha-1 as routine or preferred chronic hepatitis B therapy.
- Observational Peptides of pineal gland and thymus prolong human life, Neuro Endocrinol Lett (2003) 266-person elderly cohort. Mortality reported roughly 2 to 4 fold lower over 6 years, and acute respiratory disease incidence 2.0 to 2.4 fold lower. Single-source and never independently replicated.
- RCT Severe COVID-19 hospital mortality with thymalin, Adv Gerontol (2022) Reported hospital mortality of 40.9% for basic care, 28.4% with tocilizumab and 20.6% with thymalin. Language-version mortality figures disagree and the source report flags it.
- Preclinical Thymalin effects on human hematopoietic stem cell differentiation, Bull Exp Biol Med (2020) In human hematopoietic stem cell culture, thymalin raised the mature T-cell marker CD28 about 6.8 fold and cut CD44 and CD117 by 2 to 3 fold.
- Systematic review Natural and synthetic thymic peptides as therapeutics for immune dysfunction, Int J Immunopharmacol (1997) Characterizes thymalin as a calf-thymus extract isolated by mild acid extraction and used as an immunocorrector.
- Systematic review Thymalin composition and respiratory immune indications, review (2023) Describes thymalin as a polypeptide thymus extract containing the active dipeptides KE and EW, with reported efficacy in ARDS, COPD and severe COVID.
Glossary
Quick reference for the medical and technical terms used in this comparison.
- TA-1 Thymosin Alpha-1
- A defined 28-amino-acid thymic peptide. The generic drug name is thymalfasin, and it is approved in roughly 35 countries though not in the United States.
- Zadaxin Branded thymalfasin
- The branded synthetic thymosin alpha-1 product sold in multiple non-US countries. It is not FDA-approved in the United States.
- Thymalin Calf-thymus peptide extract
- A low-molecular-weight mixture of thymic peptides extracted from calf thymus by mild acid extraction. A mixture, not one defined molecule.
- Immunocorrector Immune-restoring agent
- The Russian clinical term for an agent meant to restore or rebalance immune function rather than simply suppress or stimulate it. Thymalin is classed this way.
- CD4/CD8 Helper and cytotoxic T-cell markers
- The ratio of helper to cytotoxic T-cells. A low or distorted ratio is a common marker of immune impairment, and both peptides are aimed at normalizing it.
- TLR9 Toll-Like Receptor 9
- A receptor on immune cells that detects danger signals and helps activate dendritic-cell antigen presentation. Thymosin alpha-1 signals through it, thymalin has no equivalent defined target.
- Th1 T-helper type 1 response
- The immune program that emphasizes antiviral and anti-tumor cellular immunity. Thymosin alpha-1 pushes polarization toward it.
- mHLA-DR Monocyte HLA-DR expression
- A marker of how well monocytes can present antigen. Low expression signals immune paralysis in critical illness, and the ETASS sepsis trial tracked its improvement.
- Peptide bioregulator Khavinson bioregulator
- The framing used by the St. Petersburg program for short peptides proposed to enter cells, reach the nucleus and adjust gene expression. Thymalin is its immune pillar.
